#South Korea #Seoul #Seegene #CURECA #STAgora

Seegene Expands European Footprint with New Subsidiary in France

Seegene, Inc., a prominent name in the realm of molecular diagnostics, has recently unveiled its new subsidiary located in France. This strategic move marks France as the eighth country to host a Seegene subsidiary, and it is the third in Europe following Italy and Germany. The establishment aims to strengthen Seegene's foothold in one of Europe’s largest molecular diagnostics markets, catering to a growing demand for innovative health solutions.

The French Diagnostic Market

France, holding the title of the second largest molecular diagnostics market in Europe, showcases a significant demand for services focused on sexually transmitted infections (STIs), gastrointestinal infections, and respiratory viruses. According to Grand View Research, Inc., the French market alone is valued at approximately €600 million, accounting for about 15% of the total European MDx market. In terms of performance, Germany leads with a 19% market share.

Given these statistics, Seegene is positioned to enhance its local operations and cater to the increasing needs of the healthcare sector by offering a diverse range of diagnostic products. The company aims not only to drive sales of existing diagnostics but also to introduce a broader portfolio that includes tests for cervical cancer and other multiplex diagnostic categories.

Enhancing Local Connections

The opening of the new subsidiary is designed to improve customer engagement and foster robust collaborations with healthcare stakeholders. Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, emphasized the importance of this new venture. He stated, "In the French market, where the landscape is divided between private and public sectors, the ability to swiftly deliver innovative products and respond to laboratory needs is crucial for competitive success."

By establishing this subsidiary, Seegene will gain deeper insights into the French healthcare landscape, allowing it to better serve its clientele and promote more efficient in vitro diagnostic solutions through localized expertise.

Future Innovations in Molecular Diagnostics

Seegene’s French subsidiary is also positioned to serve as a strategic platform for rolling out its innovative diagnostic solutions across Europe. Notably, the company is currently developing CURECA™, a fully automated PCR testing system, and STAgora™, a real-time diagnostic data analysis and forecasting platform. Both solutions represent the cutting edge of diagnostic technology and will play a vital role in enhancing the efficiency of molecular diagnostics in the region.

The establishment of this new subsidiary increases Seegene's global distribution network, which now consists of eight international sales subsidiaries and 90 distributors across 94 countries. With approximately 93% of Seegene’s total revenue generated from international sales by the first half of 2025, and 63% coming from Europe, this region remains a key driver for the company’s growth trajectory.

In summary, the launch of Seegene's subsidiary in France enhances its capacity to deliver localized support, fosters meaningful connections within the healthcare industry, and positions the company well for future innovations in molecular diagnostics. As Seegene continues to grow, its commitment to advancing healthcare through cutting-edge diagnostic technologies remains a priority.

For more information about Seegene and its revolutionary MDx products, visit Seegene.com or follow the company on LinkedIn.